Tykerb® is the brand name used for lapatinib in the United States and certain other countries. Tyverb® is the brand name used for lapatinib in Switzerland and is the proposed trade name in the ...

In recent years, new anti-HER2 drugs have entered the market, including lapatinib (brand name Tyverb or Tykerb), though this drug is currently only used to treat advanced HER2-positive breast cancer.

This was the day the FDA approved a novel compound, lapatinib, for patients with HER2–positive advanced or metastatic breast cancer who have received prior therapy including an anthracycline ...

Review the side-effects of Lapatinib as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

A planned interim review of early data from ALTTO a Phase III, four arm study of adjuvant lapatinib (Tykerb/Tyverb®), trastuzumab, their sequence and their combination in patients with HER2 ...

Lapatinib could be used to treat inflammatory breast cancer, an aggressive from of the disease which represents up to one tenth of malignant breast cancer cases. The findings of this phase II ...

Lapatinib reduces the number of large brain metastases in a mouse model of metastatic breast cancer, relative to untreated mice, researchers report. Lapatinib reduces the number of large brain ...